| | Home | Back To Index | |
|
|
||||||||||||
|
This report reviews, analyzes and sizes the markets for prescription medicines used to address diseases and conditions that predominantly affect persons age 50 and older. It focuses on the large U.S. market, with five-year revenue projections to 2015. It also presents merger and acquisition activity, research and development (R&D) initiatives and venture capital activity for current and emerging drug developers. Specific market segments examined include: - Alzheimer's disease - Arthritis - Cancer - Cardiovascular disease - Diabetes - Erectile dysfunction - Eye disease - Hair loss - High cholesterol - Hypertension - Kidney disease - Osteoporosis - Parkinson's disease - Stroke - Wrinkles In 2010, sales of these drugs used by exclusively persons age 50 and older were $50 billion. Through 2015, sales will expand by 5.3% per year to reach more than $64 billion. On a segment by segment basis, medicines used for wrinkle reduction will exhibit the greatest growth at 17.7% per year, followed by drugs used to address Alzheimer's disease at 12.1% per year. Historical information for this report was gathered from a wide variety of published sources including company reports and filings, government documents, legal filings, trade journals, newspapers and business press, analysts' reports and other sources. Interviews with company representatives and other experts were conducted to capture the perspectives from industry participants' point of view and assess trends, and form the basis of the forecasting and competitive analysis. More than 200 detailed tables and figures provide key data about revenues and market size, market share and segments. Internet links help readers access companies' own web sites for further review. Lists the major and emerging players discussed in this report:
Executive Summary 1. U.S. Drug Market Overview and Trends 1.1 U.S. Drug Market by Segment for All Ages, 2010 - 2015 Table 1.1: Total U.S. Market for Drugs of Aging (All Ages), 2010 - 2015, in Millions Table 1.2: Total U.S. Market for Drugs of Aging (All Ages), by Segment, 2010 - 2015, in Millions Figure 1.1: Total U.S. Market for Drugs of Aging (All Ages), Segment Share in 2010 Figure 1.2: Total U.S. Market for Drugs of Aging (All Ages), Segment Share in 2015 1.2 U.S. Drug Market by Segment for Aged Population, 2010 - 2015 Table 1.3: Total U.S. Market for Drugs of Aging (Aged Population), 2010 - 2015, in Millions Table 1.4: Total U.S. Market for Drugs of Aging (Aged Population), by Segment, 2010 - 2015, in Millions Figure 1.3: Total U.S. Market for Drugs of Aging (Aged Population), Segment Share in 2010 Figure 1.4: Total U.S. Market for Drugs of Aging (Aged Population), Segment Share in 2015 1.2.1 Market Size and Forecast (Include Table 1.5-1.19) 1.2.2 U.S. Sales of Drugs and Share for the Diseases of Aging 1.2.2.1 Alzheimer's Disease 1.2.2.2 Arthritis 1.2.2.3 Cancer 1.2.2.4 Cardiovascular Disease 1.2.2.5 Diabetes 1.2.2.6 Erectile Dysfunction 1.2.2.7 Eye Disease 1.2.2.8 Hair Loss 1.2.2.9 High Cholesterol 1.2.2.10 Hypertension 1.2.2.11 Kidney Disease 1.2.2.12 Osteoporosis 1.2.2.13 Parkinson's Disease 1.2.2.14 Stroke 1.2.2.15 Wrinkles 1.3 Market Drivers 1.3.1 U.S. Demographic Data for the Entire Population and Aged Population: the Effect of Aging Table 1.20: U.S. Demographic Data (Age) and Trends in Millions of Persons Table 1.21: U.S. Demographic Data (Age) and Trends for Aged Population in Millions of Persons 1.3.2 U.S. Demographic Data for the Entire Population and Aged Population: the Effect of Obesity Table 1.22: U.S. Demographic Data (Obesity) and Trends in Millions of Persons 1.3.3 U.S. Demographic Data for the Entire Population and Aged Population: the Effect of Rising Medication Usage Table 1.23: U.S. Usage of Prescription Medicines Each Year in Millions of Persons 1.4 Advanced Biotechnology 1.4.1 Overall Trends 1.4.2 New Trends and Personalized Medicine Table 1.24: Total U.S. Sales of Personalized Medications, 2009 vs. 2010 Table 1.25: Pipeline for New Personalized Medicine by Segment 1.5 Market Restraints for the Diseases of Aging 1.5.1 Rising Usage of Generics Table 1.26: U.S. Usage of Prescription Generic Medicines vs. Branded Medicines by Segment 1.6 New Products Table 1.27: New Product Information by Segment 1.7 Leading Manufacturers, New Companies and Venture Companies by Segment 1.7.1 Leading Manufacturers Table 1.28: Leading Manufacturers of Branded Prescription Medicines Used by the Aged Population Table 1.29: Leading Manufacturers of Generic Prescription Medicines Used by the Aged Population 1.7.2 Personalized Medicine Manufacturers Table 1.30: Leading Manufacturers of Personalized Medicines Used by the Aged Population 1.7.3 New/Emerging Manufacturers Table 1.31: New/Emerging Manufacturers of Medicines Used by the Aged Population 1.7.4 Venture Companies Table 1.32: Venture Companies Involved With Medicines Used by the Aged Population 2. Individual Drug Product Market Trends and Directions (Include Table 2.1-2.132) Common Research Items: 1) Market Size for U.S. Aged Population, 2010 - 2015 2) Drug Sales and Share, 2010 vs. 2012 - Branded Drug Sales and Share, 2010 vs. 2012 - Generic Drug Sales and Share, 2010 vs. 2012 3) Pipeline Drugs - Pipeline for New Branded Drugs - Generic Drugs 4) Personalized Medicine - Current Personalized Medicine - New Personalized Medicine Pipeline 5) Major M&A Activity by Companies - Leading Company R&D for Drugs - New Company R&D for Drugs - Venture Company R&D for Drugs 2.1 Alzheimer's Disease 2.2 Arthritis 2.3 Cancer 2.4 Cardiovascular Disease 2.5 Diabetes 2.6 Erectile Dysfunction 2.7 Eye Disease 2.8 Hair Loss 2.9 High Cholesterol 2.10 Hypertension 2.11 Kidney Disease 2.12 Osteoporosis 2.13 Parkinson's Disease 2.14 Stroke 2.15 Wrinkles 3 U.S. R&D Activity and Road Map for Future Direction by Market Segment (Include Table 3.1-3.15) 3.1 Alzheimer's Disease 3.2 Arthritis 3.3 Cancer 3.4 Cardiovascular Disease 3.5 Diabetes 3.6 Erectile Dysfunction 3.7 Eye Disease 3.8 Hair Loss 3.9 High Cholesterol 3.10 Hypertension 3.11 Kidney Disease 3.12 Osteoporosis 3.13 Parkinson's Disease 3.14 Stroke 3.15 Wrinkle Reduction 4. Positions, Alliances, Patent Issues and R&D Strategies for Leading Manufacturers 4.1-4.40 (total 40 manufacturers) 5. Important Findings and Recommendations for Business Opportunities 5.1 Generics 5.2 Indication Expansions Table 5.1: Pipeline for Indication Expansion Opportunities 5.3 Personalized Medicine 6. Appendix 6.1 Selected Companies Mentioned in this Report Table 6.1: Major Developers of Prescription Medicines for the Aged Population FOR ORDER OR INQUIRY, PLEASE CLICK "ORDER / INQUIRY FORM" |